New therapies in the management of hepatitis C virus

Current Opinion in Gastroenterology

Volumn 26, Issue 3, 2010, Pages 196-201

  Michaels, Anthony J ^a   Nelson, David R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Hepatitis C; Novel therapies; Polymerase inhibitors; Protease inhibitors

Indexed keywords

4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; ABT 333; ANTIVIRUS AGENT; BI 207127; BOCEPREVIR; FILIBUVIR; GS 9190; IDX 184; MK 3281; PEGINTERFERON; PSI 7851; RG 7128; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VCH 222; VCH 916;

ANTIVIRAL THERAPY; CLINICAL TRIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; RASH; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS RESISTANCE;

HEPATITIS C; HIV PROTEASE INHIBITORS; HUMANS; RIBAVIRIN;

EID: 77951295991     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283383c8f     Document Type: Review

References (36)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20:1-16. (Pubitemid 30421405)
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714. (Pubitemid 46780630)
3. Verna EC, Brown RS Jr. Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis 2008; 12:637-659. (Pubitemid 351952468)
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
6. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
7. Pereira AA, Jacobson IM. New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol 2009; 6:403-411.
8. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
9. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
10. Kwo P, Lawitz E, McCone J, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment-naïve subjects with genotype-1 chronic hepatitis C [abstract 4]. J Hepatol 2009; 50 (Suppl1):S4.
11. Everson GT, Dusheiko GM, Ferenci P, et al. Telaprevir, peginterferon alfa-2a and ribavirin improved rates of sustained virologic response (SVR) in 'difficultto-cure' patients with chronic hepatitis C (CHC): a pooled analysis from the PROVE1 and PROVE2 trials [abstract 1565]. Hepatology 2009; 50 (Suppl 4): 1025A.
12. Marcellin P, Forns X, Goeser T, et al. Virologic analysis of patients receiving telaprevir administered q8 h or q12 h with peginterferon-alfa-2a or-alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis: study C208 [abstract 194]. Hepatology 2009; 50:395A. 48 weeks.
13. Schiff E, Poordad F, Jacobson I, et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness [abstract 104]. J Hepatol 2008; 48:S46.
14. McHutchison JG, Manns MP, Muir A, et al. PROVE3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior nonresponse, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy [abstract 66]. Hepatology 2009; 50:334A-335A.
15. Shiffman ML, Berg T, Poordad F, et al. A study of telaprevir combined with peginterferon-alfa-2a and ribavirin in subjects with well documented nonresponse or relapse after previous peginterferon-alfa-2a and ribavirin treatment: interim analysis [abstract 1852]. Hepatology 2008; 48:1135A-1136A.
16. Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy [abstract LB9]. Hepatology 2007; 46:862A-863A.
17. Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days [abstract 66]. J Hepatol 2008; 48 (Suppl 2):S29.
18. Rodriguez-Torres M, Lalezari J, Gane EJ, et al. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with PEG-IFN and ribavirin: subanalysis by race/ethnicity, weight and HCV genotype [abstract 1899]. Hepatology 2008; 48:1160A.
19. Gane EJ, Rodriguez-Torres M, Nelson DR, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior nonresponders: interim results of R7128 1,500mg bid with PEG-IFN and ribavirin for 28 days [abstract LB10]. Hepatology 2008; 48:1024A.
20. McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52:1604-1612. (Pubitemid 351614649)
21. Nelson D, Pockros PJ, Godofsky E, et al. High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40kd) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin [abstract 993]. J Hepatol 2008; 48:S371.
22. Rodriguez-Torres M, Lawitz E, Flach S, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following single and 3 day multiple ascending oral doses in healthy volunteers and patients with chronic HCV infection [abstract LB17]. Hepatology 2009; 50:11A.
23. Lalezari J, Asmuth D, Casiro A, et al. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C [abstract LB17]. Hepatology 2009; 50:11A-12A.
24. Bavisotto L, Wang CC, Jacobson IR, et al. Antiviral, pharmacokinetic and safety data forGS 9190, a nonnucleoside HCV NS5b polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects [abstract 49]. Hepatology 2007; 46 (Suppl 1):255A.
25. Jacobson I, Pockros P, Lalezari J, et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naïve patients chronically infected with HCV genotype 1 [abstract 1052]. J Hepatol 2009; 50 (Suppl 1):S382.
26. Larrey D, Benhamou Y, Lohse AW, et al. Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C [abstract 1054]. J Hepatol 2009; 50 (Suppl 1):S383.
27. Lawitz E, Cooper C, Rodriguez-Torres M, et al. Safety, tolerability and antiviral activity of VCH-916, a novel nonnucleoside HCV polymerase inhibitor in patients with chronic HCV genotype-1 infection [abstract 92]. J Hepatol 2009; 50 (Suppl 1):S37.
28. Bedard J, Nicolas O, Bilimoria D, et al. Identification and characterization of VCH-222, a novel potent and selective nonnucleoside HCV polymerase inhibitor [abstract 935]. J Hepatol 2009; 50 (Suppl 1):S340.
29. Cooper C, Larouche R, Bourgault B, et al. Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals [abstract 935]. J Hepatol 2009; 50 (Suppl 1):S342.
30. Brainard D, Wright DH, Sneddon K, et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-3281 in healthy subjects [abstract 935]. J Hepatol 2009; 50 (Suppl 1):S341.
31. Rodriguez-Torres M, Lawitz E, Cohen D, et al. Treatment-naive, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone [abstract 935]. Hepatology 2009; 50:5A.
32. Gane EJ, Roberts SK, Stedman C, et al. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1 [abstract 935]. J Hepatol 2009; 50 (Suppl 1):S380.
33. Zeuzem S, Sulkowski M, Lawitz E, et al. Efficacy and safety of albinterferon alfa-2B in combination with ribavirin in treatment-naive, chronic hepatitisCgenotype 1 (CHC G1) patients [abstract 1041]. J Hepatol 2009; 50 (Suppl 1): S377.
34. Nelson D, Benhamou Y, Chuang WL, et al. Efficacy and safety results of albinterferon alfa-2B in combination with ribavirin in interferon-alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C [abstract 1042]. J Hepatol 2009; 50 (Suppl 1):S378.
35. Lawitz E, Muir AJ, Poordad F, et al. Treatment week 24 results of weight-based taribavirin versus weight-based ribavirin, both with peginterferon alfa-2b, in naive chronic hepatitis C, genotype 1 patients [abstract 272]. Hepatology 2008; 48:433A.
36. Poordad F, Lawitz E, Hassanein T, et al. Sustained virologic response (SVR) results for weight-based-taribavirin versus weight-based-ribavirin, in naive chronic hepatitis C, genotype 1 patients [abstract 65]. Hepatology 2009; 50:334A.